Integrated and seamless execution of drug discovery programs: Concept to clinic
SynVent is Syngene’s proprietary drug discovery platform for enabling fully integrated therapeutic drug discovery and development across small molecules, new modalities and biologics. With SynVent, you get professional and experienced support for your drug discovery projects from concept to clinic. We offer advice on integrated drug discovery programs and can also work as an extension of your internal team, helping you set objectives, execute your scientific plan, and support you in making the right decisions at the right time.
A typical integrated drug discovery project with SynVent
The journey from conceptualization to clinical development is intricate and often lacks a straightforward path. Our specialized SynVent team has been assembled to offer comprehensive support at each stage of your discovery journey. Through SynVent, we offer a one-stop solution for managing and coordinating drug discovery projects.
SynVent offers seamless progression — discovery to development
Our team members have decades of experience working in biotechs and pharma as scientific leaders. We understand data, how to apply the most impactful technologies and computational tools, and how to ensure your project has an effective translational path to clinical efficacy. SynVent seamlessly integrates synthetic and medicinal chemistry, biology, DMPK, and toxicology while leveraging our extensive drug discovery knowledge and project management proficiency. This approach lets customers concentrate on essential milestones and their core scientific requirements.
Customer Speak
I’ve witnessed multiple lead compounds and discovery efforts born out of collaborative research between Bangalore and the US, culminating in over 20 drug candidates across various therapeutic areas. This includes refined CMC processes furnished with translational medicine from locally generated Phase 0 patient data and covering a broad range of drug platforms across small molecules and biologics. Within the context of this work, I’ve observed the entire continuum of ground-breaking research, novel ideas brought to fruition, talented individuals growing into brilliant scientists, a willingness to get things done, and a sense of urgency from the lab through to management -- all collectively rendering Syngene an ideal partner for modest biotech to large pharma.
Currently, we are deeply engaged with the SynVent team in five unique neuroscience programs from early to late discovery.
We definitely consider SynVent team as a partner of choice offering scientific excellence in drug discovery, a true project team spirit and excellent project management to coordinate teams combined with a very high productivity level at the bench.
At Qubit Pharmaceuticals, we have been delighted to partner with Syngene Integrated Drug Discovery (IDD) team on a hit to lead project aiming at developing new anti-cancer therapy.
Thanks to Syngene integrated approach we have worked in a fully collaborative and project driven way to (i) implement an appropriate flow chart for hit characterization and optimization (ii) deliver optimized hits from different chemical series. Assay development for the target of interest was very challenging and we have benefited from the high scientific expertise and proactivity of Syngene biology team to identify the most relevant assays (biochemical, biophysical and cellular). The quality of the chemistry team has been outstanding as well in term of productivity and problem solving as in terms of structure-activity-relationship (SAR) analysis and new designs proposals which were filtered using Qubit unique technology to prioritize the next compound to synthesize. We have also greatly appreciated the high flexibility of the team when we had to change priorities, which is not always the case when we use pure fee for service offers. The great advantage of the IDD format is that we have been able to work as a true project team with very good and seamless communication combined with very efficient coordination to accelerate significantly the project progression. Finally, this first phase of the collaboration has been very successful with the identification of 4 different chemical series with low nanomolar activity and preliminary ADMET data which will be used to implement the next lead optimization step.
We are looking forward to starting the second phase of this project with Syngene IDD team and delivering optimized leads in the coming months.
Dr. Robert Marino
CEO, Qubit Pharmaceuticals
